Advancing Innovation
The World’s only Available Recombinant Acellular Pertussis Vaccine (RAPV).
RAPV contains genetically-inactivated Pertussis Toxin (PTgen). The vaccines, especially the monovalent PTgen, are poised for pregnant woman and throughout life vaccinations.
The safety, immunogenicity and antibody persistence induced after one single booster dose of BioNet’s RAPV were demonstrated in numerous randomized clinical trials, notably amongst adults in Australia, adolescents in Switzerland, as well as vulnerable populations such as pregnant women and elderly in Thailand.
The vaccine is licensed in Asia and is included in the pertussis maternal immunization program for pregnant women in Thailand. The MAA of vaccine has also been submitted to the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA).
Vaccine Development and Project Management
BioNet leads the rapid advancement of genetic vaccines using cutting-edge mRNA technology. Our established, clinically-proven mRNA platform ensures safety and strong immunogenicity, demonstrated in SARS-CoV-2 vaccines. The unique “plug and play” design allows quick adaptation to emerging variants and potential pandemics.
With a proven track record in global collaborations, BioNet partners with PATH, BMGF, Institut Pasteur, CEPI, IVI, and leading universities. Our extensive vaccine development capabilities encompass antigen design, preclinical activities, clinical material production, clinical trials, and project management.